Profile data is unavailable for this security.
About the company
ResMed Inc. is a holding company. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. Its segments include Sleep and Breathing Health segment and the Residential Care Software segment. It also operates a Software as a Service (SaaS) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. Its products and solutions are designed to improve patients' quality of life and reduce the impact of chronic disease. Its cloud-based digital health software applications, along with its devices, are designed to provide connected care.
- Revenue in USD (TTM)5.02bn
- Net income in USD1.31bn
- Incorporated1994
- Employees9.98k
- LocationResmed Inc9001 Spectrum Center BlvdSAN DIEGO 92123-1438United StatesUSA
- Phone+1 (858) 746-2400
- Fax+1 (302) 636-5454
- Websitehttps://www.resmed.com/
Mergers & acquisitions
| Acquired company | RMD:NYQ since announced | Transaction value |
|---|---|---|
| VirtuOx Inc | 9.02% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Insulet Corp | 2.20bn | 402.20m | 19.94bn | 3.90k | 51.01 | 14.99 | 41.05 | 9.07 | 5.56 | 5.56 | 29.72 | 18.91 | 0.7161 | 1.49 | 6.08 | 563,820.50 | 13.10 | 6.00 | 15.50 | 7.03 | 70.39 | 67.05 | 18.29 | 9.22 | 3.63 | 49.39 | 0.5603 | 0.00 | 22.07 | 22.92 | 102.76 | 104.84 | -4.75 | -- |
| Steris PLC | 5.46bn | 610.12m | 22.09bn | 17.79k | 36.46 | 3.34 | 20.31 | 4.05 | 6.16 | 6.20 | 55.11 | 67.18 | 0.5148 | 4.87 | 5.32 | 306,938.50 | 5.77 | 5.04 | 6.36 | 5.51 | 44.01 | 43.75 | 11.20 | 10.69 | 1.39 | 12.76 | 0.236 | 37.51 | 6.24 | 12.49 | 10.64 | 8.40 | 11.52 | 8.99 |
| DexCom Inc | 4.15bn | 535.20m | 32.98bn | 10.30k | 64.49 | 14.55 | 43.37 | 7.95 | 1.30 | 1.30 | 10.11 | 5.78 | 0.6269 | 2.89 | 3.89 | 402,718.40 | 8.09 | 8.79 | 12.44 | 11.75 | 60.72 | 64.97 | 12.90 | 14.90 | 1.32 | -- | 0.5246 | 0.00 | 11.34 | 22.27 | 6.41 | 41.63 | 14.79 | -- |
| Agilent Technologies Inc | 6.63bn | 1.17bn | 33.05bn | 18.00k | 28.64 | 5.38 | 22.91 | 4.99 | 4.06 | 4.06 | 23.09 | 21.61 | 0.576 | 3.08 | 5.07 | 370,279.30 | 10.13 | 10.93 | 12.25 | 13.09 | 53.77 | 53.35 | 17.59 | 17.93 | 1.60 | 24.95 | 0.3629 | 21.83 | -4.73 | 4.75 | 3.95 | 3.77 | 19.36 | 7.80 |
| GE HealthCare Technologies Inc | 19.80bn | 2.18bn | 34.91bn | 53.00k | 16.03 | 3.80 | 12.38 | 1.76 | 4.76 | 4.76 | 43.13 | 20.07 | 0.6018 | 5.54 | 4.51 | 373,547.20 | 6.84 | -- | 9.67 | -- | 41.99 | 40.35 | 11.37 | 10.78 | 0.7601 | 8.18 | 0.483 | 1.19 | 0.6138 | 3.41 | 43.48 | 3.82 | 3.91 | -- |
| Resmed Inc | 5.02bn | 1.31bn | 37.60bn | 9.98k | 28.79 | 6.78 | 24.72 | 7.49 | 8.91 | 8.91 | 34.05 | 37.83 | 0.6983 | 2.45 | 5.65 | 503,159.20 | 18.26 | 14.24 | 20.73 | 16.53 | 58.76 | 56.85 | 26.15 | 20.35 | 2.49 | 58.86 | 0.1082 | 32.62 | 10.95 | 12.44 | 13.75 | 19.98 | 8.23 | 5.89 |
| IDEXX Laboratories Inc | 3.93bn | 894.97m | 41.72bn | 11.00k | 47.93 | 28.92 | 40.54 | 10.61 | 10.82 | 10.82 | 47.53 | 17.93 | 1.20 | 3.87 | 6.81 | 357,439.60 | 27.26 | 28.11 | 40.01 | 42.15 | 61.28 | 59.56 | 22.76 | 22.19 | 0.8111 | 53.37 | 0.3937 | 0.00 | 6.46 | 10.12 | 5.07 | 15.73 | -3.35 | -- |
| Edwards Lifesciences Corp | 5.54bn | 1.44bn | 44.69bn | 15.80k | 31.43 | 4.41 | 28.31 | 8.07 | 2.42 | 7.00 | 9.31 | 17.28 | 0.4867 | 0.984 | 7.45 | 350,557.00 | 12.63 | 14.52 | 14.28 | 16.61 | 79.38 | 79.01 | 25.95 | 25.54 | 3.66 | -- | 0.0554 | 0.00 | 8.57 | 4.58 | 14.55 | 5.94 | 0.2857 | -- |
| Veeva Systems Inc | 2.86bn | 780.66m | 45.18bn | 7.29k | 58.65 | 7.25 | 55.00 | 15.82 | 4.71 | 4.71 | 17.25 | 38.11 | 0.4093 | -- | 6.06 | 391,622.10 | 11.19 | 11.33 | 13.85 | 14.35 | 75.50 | 72.60 | 27.34 | 23.96 | -- | -- | 0.00 | 0.00 | 16.20 | 19.99 | 35.84 | 18.85 | 36.56 | -- |
| Becton Dickinson and Co | 20.87bn | 1.50bn | 51.85bn | 74.00k | 35.03 | 2.05 | 13.41 | 2.48 | 5.16 | 5.16 | 71.96 | 88.07 | 0.3842 | 3.32 | 7.47 | 281,986.50 | 2.76 | 2.55 | 3.20 | 2.92 | 44.68 | 45.30 | 7.18 | 7.29 | 0.6427 | 7.18 | 0.4329 | 76.93 | 4.16 | 3.14 | 15.99 | 10.56 | -5.40 | 4.29 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2025 | 17.81m | 12.13% |
| BlackRock Fund Advisorsas of 31 Mar 2025 | 8.89m | 6.05% |
| SSgA Funds Management, Inc.as of 31 Mar 2025 | 6.55m | 4.46% |
| Walter Scott & Partners Ltd.as of 31 Mar 2025 | 4.17m | 2.84% |
| Geode Capital Management LLCas of 31 Mar 2025 | 4.12m | 2.80% |
| Morgan Stanley & Co. LLCas of 31 Mar 2025 | 2.84m | 1.94% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2025 | 1.35m | 0.92% |
| Invesco Capital Management LLCas of 31 Mar 2025 | 1.30m | 0.88% |
| BlackRock Advisors (UK) Ltd.as of 31 Mar 2025 | 1.15m | 0.78% |
| BlackRock Investment Management (UK) Ltd.as of 31 Mar 2025 | 1.06m | 0.72% |
